Female Infertility Drugs Market by Route of Administration and Geography - Forecast and Analysis 2021-2025

The female infertility drugs market share is expected to increase by USD 538.69 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.71%.

This female infertility drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers female infertility drugs market segmentation by route of administration (parenteral, oral, and vaginal) and geography (North America, Europe, Asia, and ROW). The female infertility drugs market report also offers information on several market vendors, including AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd. among others.

What will the Female Infertility Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Female Infertility Drugs Market Size for the Forecast Period and Other Important Statistics

 

Female Infertility Drugs Market: Key Drivers, Trends, and Challenges

The adverse effects and high cost of non-therapeutics are notably driving the female infertility drugs market growth, although factors such as the availability of alternative treatment options may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the female infertility drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Female Infertility Drugs Market Driver

The adverse effects and high cost of non-therapeutics will boost the popularity of female infertility drugs. Various ART procedures, including IVF, IUI, and ICSI are available as alternatives to medications for the treatment of female infertility. However, these non-therapeutics are associated with several adverse effects, such as ovarian hyperstimulation syndrome, multiple-gestation pregnancies, multiple-birth infants, premature labor, low birth weight, and risk of cesarean delivery. Moreover, ART procedures are highly expensive, which act as a challenge to patient adherence to these methods. These factors will increase the use of therapeutics for treating female infertility, consequently fueling the growth of the market during the forecast period.

Key Female Infertility Drugs Market Trend

The introduction of biosimilars will be one of the critical female infertility drugs market trends influencing the growth of the market. As biologics are highly expensive and are not affordable by everyone, market vendors are focusing on launching new and cost-effective biosimilars. For instance, Ovaleap, a biosimilar to GONAL-f (follitropin alfa) from Merck KGaA, was launched by Teva Pharmaceutical Industries Ltd. Another version of biosimilar to GONAL-f named BEMFOLA was approved in Australia. The introduction of these low-cost biosimilars will promote patient adherence and boost the demand for female infertility drugs.

Key Female Infertility Drugs Market Challenge

Various alternatives to medications, such as surgical procedures and ART, are available for the treatment of female fertility. Surgical treatments are helpful in correcting pelvic abnormalities such as uterine fibroids and pelvic adhesions. The most common surgical procedures are laparoscopy, hysteroscopy, and abdominal myomectomy (removal of uterine fibroids). The main type of ART is IVF, which involves extracting a woman's eggs, fertilizing them in the laboratory, and then transferring the resulting embryos into the woman's uterus through the cervix. The availability of such effective alternative options is expected to hamper the growth of the global female infertility drugs market during the forecast period. 

This female infertility drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Female Infertility Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• Aurobindo Pharma Ltd.
• Dr. Reddys Laboratories Ltd.
• Ferring B.V.
• Lupin Ltd.
• Merck KGaA
• Mylan NV
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

 

This statistical study of the female infertility drugs market encompasses successful business strategies deployed by the key vendors. The female infertility drugs market is fragmented and the vendors are deploying growth strategies such as distributing their products globally through their subsidiaries and other distribution channels to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The female infertility drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Female Infertility Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

35% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for female infertility drugs in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe.

The growing prevalence of female infertility, adverse outcomes, and the high cost of non-therapeutic treatment will facilitate the female infertility drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Route of Administration Segments in the Female Infertility Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The female infertility drugs market share growth by the parenteral segment will be significant during the forecast period. Drugs approved in this segment are mainly peptide hormonal preparations that mimic the physiological effects of gonadotropins. These hormonal analogs are primarily used as fertility medication for ovarian hyperstimulation and reversal of ovulation. The parenteral route is more convenient for these peptide drugs, which are prone to degradation when administered through the oral route. Hence, these drugs exhibit high bioavailability when administered through the parenteral route. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the female infertility drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Female Infertility Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 4.71%
Market growth 2021-2025	$ 538.69 million
Market structure	Fragmented
YoY growth (%)	3.97
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 35%
Key consumer countries	US, Canada, Germany, China, and UK
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Female Infertility Drugs Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive female infertility drugs market growth during the next five years
• Precise estimation of the female infertility drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the female infertility drugs industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of female infertility drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch